CRISPR speculation

Speculation on what’s behind climbing CRISPR stocks

CRISPR companies have gained a collective $1.9 billion in market cap this quarter and two investors who spoke with BioCentury believe the run-up is primarily due to M&A speculation following the acquisitions of CAR T companies Kite Pharma Inc. and Juno Therapeutics Inc.

Since Dec. 31, CRISPR

Read the full 468 word article

User Sign In